plekhf2 Antibody

What is PLEKHF2 and what are its primary functions in cells?

PLEKHF2, also known as Phafin2, is a protein containing both PH (pleckstrin homology) and FYVE domains. It primarily functions in:

• Early endosome fusion upstream of RAB5, regulating receptor trafficking and fluid-phase transport

• Enhancement of cellular sensitivity to TNF-induced apoptosis

• Coordination of actin organization at forming macropinosomes

• Promotion of recycling tubules on macropinosomes

The protein is expressed in multiple tissues including placenta, ovary, small intestine, heart, pancreas, peripheral blood mononuclear cells, and dendritic cells .

How is PLEKHF2 structurally organized and what domains are important for antibody targeting?

PLEKHF2 has a calculated molecular weight of approximately 28 kDa and contains two key structural domains:

• An N-terminal PH (pleckstrin homology) domain that typically binds phosphoinositides

• A C-terminal FYVE (Fab1, YGLO23, Vps27, and EEA1) domain that specifically recognizes phosphatidylinositol 3-phosphate (PtdIns3P)

These domains are critical for PLEKHF2's subcellular localization and function. Antibodies targeting different regions (N-terminal, central region, or C-terminal) may provide distinct insights into protein interactions and functions .

What is the subcellular localization of PLEKHF2 and how does it change during cellular processes?

PLEKHF2 demonstrates dynamic subcellular localization:

• Under normal conditions: Diffusely distributed in the cytosol

• During endocytic processes: Localizes to early endosome membranes, colocalizing with EEA1 and RAB5 at endosomal membrane fusion hot spots

• During apoptosis: May translocate to the endoplasmic reticulum in the early phase

• During autophagy induction: Co-localizes with Akt on lysosomes

This dynamic localization is critical when designing immunofluorescence experiments, as fixation methods and timing can significantly impact detection patterns.

What criteria should be considered when selecting a PLEKHF2 antibody for specific applications?

When selecting a PLEKHF2 antibody, consider:

• Target epitope location:

  • N-terminal antibodies (AA 1-70): Useful for detecting full-length protein

  • Central region antibodies (AA 71-98): Common in commercial offerings

  • C-terminal antibodies: May detect specific isoforms

• Validated applications:

  • Western blotting: Most antibodies are validated for this application

  • Immunohistochemistry: Some antibodies work in both paraffin-embedded and frozen sections

  • ELISA: Select antibodies specifically validated for this application

• Species reactivity:

  • Human-specific: When studying human cell lines or tissues

  • Cross-reactive antibodies: For comparative studies across species (many antibodies show reactivity to human, mouse, rat, chicken, and monkey)

• Clonality:

  • Polyclonal: Broader epitope recognition but potential batch variation

  • Monoclonal: Consistent specificity but more limited epitope recognition

The application should guide your selection—for example, IP applications may require antibodies targeting accessible epitopes in the native protein conformation .

How should PLEKHF2 antibodies be validated before use in critical experiments?

A systematic validation approach for PLEKHF2 antibodies includes:

• Positive controls:

  • Verified cell lines: Jurkat and Raji cells have been confirmed as positive controls

  • Tissue controls: Human tonsil for IHC applications

  • Mouse kidney tissue for cross-reactive antibodies

• Specificity validation:

  • Western blot: Confirm single band at expected molecular weight (~28 kDa)

  • Knockout/knockdown: Compare signal in PLEKHF2-depleted vs. control samples

  • Peptide competition: Pre-incubate antibody with immunizing peptide to confirm specific binding

• Application-specific validation:

  • For IHC: Test optimal dilution range (typically 1:100-1:1000) and antigen retrieval methods

  • For WB: Optimize dilution (ranges from 1:500-1:5000 depending on antibody)

  • For IF: Verify colocalization with known interacting partners (e.g., RAB5, EEA1)

Note that the observed molecular weight may not always match the calculated 28 kDa, as post-translational modifications can affect migration patterns .

How can PLEKHF2 antibodies be optimized for immunohistochemistry applications?

For optimal IHC results with PLEKHF2 antibodies:

• Sample preparation:

  • Fixation: 10% neutral buffered formalin is recommended

  • Embedding: Paraffin embedding is suitable for most applications

  • Sectioning: 4-6 μm sections provide optimal resolution

• Antigen retrieval methods:

  • Heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) is most common

  • For some antibodies, EDTA buffer (pH 9.0) may provide better results

• Protocol optimization:

  • Dilution range: Test between 1:100-1:2500 based on antibody specifications

  • Incubation: Overnight at 4°C often yields best signal-to-noise ratio

  • Detection system: HRP-polymer based systems provide better sensitivity than ABC methods

• Controls:

  • Include human tonsil as positive control tissue

  • Use isotype controls to assess non-specific binding

  • Consider parallel staining with antibodies targeting different epitopes

The subcellular localization pattern should be assessed carefully, as PLEKHF2 can show both cytoplasmic and membrane-associated staining depending on the cellular context .

What are the critical parameters for successful Western blot detection of PLEKHF2?

For optimal Western blot detection of PLEKHF2:

• Sample preparation:

  • Lysis buffer: RIPA buffer supplemented with phosphatase and protease inhibitors

  • Denaturing conditions: Standard Laemmli buffer with β-mercaptoethanol

  • Loading amount: 20-40 μg of total protein for cell lysates

• Electrophoresis and transfer:

  • Gel percentage: 10-12% SDS-PAGE gels resolve the 28 kDa protein effectively

  • Transfer conditions: Semi-dry transfer at 15V for 30 minutes or wet transfer at 100V for 1 hour

• Antibody incubation:

  • Primary antibody dilution:

    • 1:1000-1:5000 for high-sensitivity antibodies

    • 0.04-0.4 μg/mL for concentration-specified antibodies

  • Incubation conditions: Overnight at 4°C in 5% BSA or milk in TBST

  • Secondary antibody: HRP-conjugated anti-rabbit at 1:5000-1:10000

• Detection:

  • Enhanced chemiluminescence (ECL) is sufficient for most applications

  • Expected band size: ~28 kDa, though variations may occur due to post-translational modifications

• Positive controls:

  • Jurkat or Raji cell lysates serve as reliable positive controls

  • Mouse kidney tissue for cross-reactive antibodies

Note that the observed molecular weight may differ from the predicted size due to post-translational modifications or the presence of splice variants .

How can PLEKHF2 antibodies be used to study protein-protein interactions?

PLEKHF2 antibodies can be utilized to study protein-protein interactions through several approaches:

• Co-immunoprecipitation (Co-IP):

  • Use 1-2 μg of PLEKHF2 antibody per 500 μg of protein lysate

  • Perform in non-denaturing conditions to preserve native protein interactions

  • Confirmed interactions include JIP4, as demonstrated by tandem affinity purification

  • Crosslinking with DSP or formaldehyde can capture transient interactions

• Proximity ligation assay (PLA):

  • Combine PLEKHF2 antibody with antibodies against suspected interaction partners

  • Particularly useful for detecting Phafin2-Akt interactions during autophagy

  • Requires antibodies raised in different species for optimal results

• Immunofluorescence co-localization:

  • Use antibodies against PLEKHF2 and interaction partners (e.g., RAB5, EEA1)

  • Particularly effective for studying endosomal localization

  • PLEKHF2 has been shown to colocalize with EEA1 and RAB5 at endosomal membrane fusion sites

• Pull-down assays:

  • LAP-tagged Phafin2 has been successfully used in tandem affinity purification

  • Mass spectrometry analysis identified JIP4 as a strong interactor with 28-fold enrichment

These methods have revealed important interactions between PLEKHF2 and proteins involved in membrane trafficking and signaling pathways.

How can PLEKHF2 antibodies be utilized to study its role in macropinocytosis and endosomal trafficking?

To investigate PLEKHF2's role in macropinocytosis and endosomal trafficking:

• Live-cell imaging with fluorescent PLEKHF2 antibody fragments:

  • Fab fragments conjugated to fluorophores can track PLEKHF2 dynamics

  • Combine with markers for early endosomes (EEA1) and macropinosomes (dextran)

  • This approach has revealed PLEKHF2's recruitment to retromer-containing tubules of macropinosomes

• Immunofluorescence co-staining protocol:

  • Fix cells at different time points after macropinocytosis induction

  • Co-stain for PLEKHF2 and JIP4 to analyze their temporal recruitment

  • Include markers for actin (phalloidin) to visualize actin reorganization at macropinosomes

  • This method demonstrated that PLEKHF2 promotes recycling tubules on macropinosomes

• Functional assays with antibody-mediated inhibition:

  • Microinjection of function-blocking PLEKHF2 antibodies

  • Monitor uptake of fluorescent dextran to assess macropinocytosis efficiency

  • Quantify the density of tubular structures on macropinosomes

• Biochemical fractionation with antibody detection:

  • Isolate early endosomal fractions using sucrose gradient centrifugation

  • Use PLEKHF2 antibodies to detect protein levels in different fractions

  • Compare with RAB5 and other endosomal markers

This multi-faceted approach has revealed that PLEKHF2 plays crucial roles in coordinating actin organization during macropinosome formation and promoting recycling tubules on macropinosomes .

What experimental approaches can be used to study PLEKHF2's role in TNF-induced apoptosis?

To investigate PLEKHF2's role in TNF-induced apoptosis:

• Apoptosis induction and monitoring:

  • Treat cells with TNF-α (10-50 ng/mL) with or without cycloheximide

  • Use PLEKHF2 antibodies to track protein localization during apoptosis progression

  • This has revealed PLEKHF2's translocation to the endoplasmic reticulum during early apoptosis

• Structure-function analysis:

  • Generate domain-specific mutants of PLEKHF2 (PH domain, FYVE domain)

  • Use antibodies to confirm expression and analyze localization of mutants

  • Assess apoptotic response to TNF-α in cells expressing these mutants

  • This approach demonstrated the importance of both domains for PLEKHF2's pro-apoptotic function

• Protein complex analysis:

  • Perform co-immunoprecipitation with PLEKHF2 antibodies at different time points after TNF-α treatment

  • Analyze associated proteins by mass spectrometry

  • Focus on changes in interactions during the apoptotic cascade

• Subcellular fractionation with antibody detection:

  • Isolate ER, mitochondrial, and cytosolic fractions at different time points after TNF-α treatment

  • Use PLEKHF2 antibodies to track protein redistribution between compartments

  • This has shown PLEKHF2's involvement in the ER-mitochondrial apoptotic pathway

These approaches have demonstrated that PLEKHF2 enhances cellular sensitivity to TNF-induced apoptosis, potentially through its redistribution to the endoplasmic reticulum and subsequent involvement in the ER-mitochondrial apoptotic pathway .

How can researchers investigate PLEKHF2's involvement in autophagy using antibody-based techniques?

To study PLEKHF2's role in autophagy:

• Autophagy induction and monitoring:

  • Induce autophagy with rapamycin or Hank's balanced salt solution

  • Use PLEKHF2 antibodies in immunofluorescence to track protein localization

  • Co-stain with Akt and lysosomal markers to visualize the Akt-Phafin2 complex on lysosomes

  • This approach revealed that PLEKHF2 co-localizes with Akt on lysosomes during autophagy

• Protein-lipid interaction analysis:

  • Perform PIP strip assays with recombinant PLEKHF2

  • Use PLEKHF2 antibodies to detect binding to specific phosphoinositides

  • This has demonstrated PLEKHF2's interaction with PtdIns(3)P, which is crucial for its lysosomal localization

• Mutational analysis:

  • Generate PtdIns(3)P interaction-defective mutants of PLEKHF2

  • Use antibodies to analyze their localization during autophagy

  • This approach showed that PtdIns(3)P binding is essential for PLEKHF2's association with lysosomal membranes

• Functional knockdown/knockout studies:

  • Perform siRNA knockdown of PLEKHF2

  • Use LC3 antibodies to monitor autophagosome formation

  • This revealed that mouse macrophages transfected with Phafin2-siRNA failed to initiate the autophagic process

This integrated approach has demonstrated that PLEKHF2 plays a crucial role in autophagy induction, particularly through its PtdIns(3)P-dependent association with lysosomes and its interaction with Akt .

What are common issues when using PLEKHF2 antibodies and how can they be resolved?

When working with PLEKHF2 antibodies, researchers may encounter several challenges:

• Inconsistent band size in Western blotting:

  • Issue: Observed molecular weight differs from the calculated 28 kDa

  • Solution: This is expected as protein mobility can be affected by post-translational modifications

  • Validation approach: Use positive control lysates from Jurkat or Raji cells

• High background in immunohistochemistry:

  • Issue: Non-specific staining obscures specific PLEKHF2 signal

  • Solution:

    • Optimize antibody concentration (try 1:100-1:2500 dilution range)

    • Use more stringent washing (0.1% Tween-20 in PBS)

    • Block with 5% BSA instead of serum

  • Validation: Include isotype control and compare staining pattern with literature

• Weak signal in immunofluorescence:

  • Issue: Low detection of PLEKHF2 despite confirmed expression

  • Solution:

    • Test different fixation methods (4% PFA vs. methanol)

    • Try antigen retrieval even for IF applications

    • Use tyramide signal amplification for weak signals

  • Optimization: PLEKHF2 may relocalize during fixation; compare live-cell imaging results

• Cross-reactivity with other proteins:

  • Issue: Antibody detects non-specific proteins

  • Solution:

    • Use antibodies targeting different epitopes for confirmation

    • Validate with PLEKHF2 knockdown/knockout samples

    • Consider using more specific monoclonal antibodies when available

• Storage-related issues:

  • Issue: Reduced antibody activity after storage

  • Solution:

    • Store at -20°C in small aliquots to avoid freeze-thaw cycles

    • Add 50% glycerol to prevent freezing damage in some formulations

    • For short-term storage (1-2 weeks), 4°C is acceptable

Following these troubleshooting approaches will help ensure reliable results when working with PLEKHF2 antibodies.

How can researchers optimize methods for detecting PLEKHF2 in challenging samples or low-expression conditions?

For detecting PLEKHF2 in challenging conditions:

• Low expression scenarios:

  • Enrichment strategies:

    • Perform subcellular fractionation to concentrate endosomal fractions

    • Immunoprecipitate PLEKHF2 before Western blotting

  • Signal amplification methods:

    • Use high-sensitivity ECL substrates for Western blotting

    • Apply tyramide signal amplification for immunohistochemistry

    • Consider quantum dot-conjugated secondary antibodies for long-lasting signals

• Difficult tissue samples:

  • Optimization of fixation:

    • Test progressive fixation times (4, 8, 12, 24 hours)

    • Compare cross-linking (formaldehyde) vs. precipitating (methanol) fixatives

  • Antigen retrieval methods:

    • Compare heat-induced (citrate, EDTA, Tris buffers) vs. enzymatic retrieval

    • Optimize pH (6.0 vs. 9.0) for maximum epitope exposure

  • Alternative detection strategies:

    • Consider chromogenic vs. fluorescent detection systems

    • Use polymer-based detection for improved sensitivity

• Precious samples with limited material:

  • Miniaturized protocols:

    • Capillary Western technology (ProteinSimple)

    • Reverse phase protein arrays

  • Multiplexing strategies:

    • Sequential stripping and reprobing

    • Multiplex immunofluorescence with spectrally distinct fluorophores

• Complex samples with high background:

  • Pre-absorption strategies:

    • Pre-absorb antibodies with tissues lacking PLEKHF2 expression

    • Use species-matched control IgG at the same concentration

  • Alternative blocking agents:

    • Test commercial protein-free blockers

    • Consider 5% milk vs. 5% BSA vs. fish gelatin for optimal results

These optimized approaches have been validated in studies detecting PLEKHF2 in diverse experimental contexts from cell lines to complex tissue samples.

What are the latest methodological advances in antibody-based detection of PLEKHF2 and related proteins?

Recent methodological advances for PLEKHF2 antibody applications include:

• Proximity-based detection technologies:

  • Proximity ligation assay (PLA):

    • Detects PLEKHF2 interactions with partners like Akt and JIP4

    • Provides single-molecule resolution of protein complexes

    • Has revealed novel interactions in the endosomal pathway

  • FRET-based antibody pairs:

    • Allows real-time monitoring of PLEKHF2 conformational changes

    • Useful for studying domain interactions during signaling events

• Super-resolution microscopy techniques:

  • STORM/PALM microscopy:

    • Achieves ~20nm resolution of PLEKHF2 localization

    • Reveals previously undetectable subendosomal distributions

  • Expansion microscopy:

    • Physical expansion of samples improves resolution with standard antibodies

    • Particularly useful for studying PLEKHF2's role at endosomal contact sites

• Antibody engineering approaches:

  • Nanobodies and single-domain antibodies:

    • Smaller size allows better penetration and epitope access

    • Reduced background in complex samples

  • Bispecific antibody fragments:

    • Target PLEKHF2 and binding partners simultaneously

    • Useful for studying transient interactions in living cells

• Integration with other technologies:

  • Mass cytometry (CyTOF) with metal-tagged antibodies:

    • Allows multiplexed detection of PLEKHF2 and dozens of other proteins

    • Useful for systems-level analysis of signaling networks

  • CITE-seq approaches:

    • Combines antibody detection with transcriptomics

    • Links PLEKHF2 protein levels to broader gene expression patterns

• Advanced computational analysis:

  • Machine learning algorithms:

    • Improve signal extraction from noisy immunofluorescence data

    • Identify subtle patterns in PLEKHF2 distribution not visible to human observers

  • Cloud-based image analysis platforms:

    • Enable collaborative analysis of large antibody-based datasets

    • Apply standardized quantification across multiple experiments

These methodological advances are beginning to reveal new insights into the dynamic behavior and interactions of PLEKHF2 in various cellular contexts .

Comprehensive FAQ Guide for PLEKHF2 Antibody Research

PLEKHF2 (Pleckstrin Homology Domain Containing, Family F With FYVE Domain Member 2) is a protein involved in critical cellular functions including endosome fusion, receptor trafficking, and apoptotic pathways. This collection of frequently asked questions addresses key considerations for researchers working with PLEKHF2 antibodies in academic settings, from basic characterization to advanced experimental applications.

What is PLEKHF2 and what are its primary functions in cells?

PLEKHF2, also known as Phafin2, is a protein containing both PH (pleckstrin homology) and FYVE domains. It primarily functions in:

• Early endosome fusion upstream of RAB5, regulating receptor trafficking and fluid-phase transport

• Enhancement of cellular sensitivity to TNF-induced apoptosis

• Coordination of actin organization at forming macropinosomes

• Promotion of recycling tubules on macropinosomes

The protein is expressed in multiple tissues including placenta, ovary, small intestine, heart, pancreas, peripheral blood mononuclear cells, and dendritic cells .

How is PLEKHF2 structurally organized and what domains are important for antibody targeting?

PLEKHF2 has a calculated molecular weight of approximately 28 kDa and contains two key structural domains:

• An N-terminal PH (pleckstrin homology) domain that typically binds phosphoinositides

• A C-terminal FYVE (Fab1, YGLO23, Vps27, and EEA1) domain that specifically recognizes phosphatidylinositol 3-phosphate (PtdIns3P)

These domains are critical for PLEKHF2's subcellular localization and function. Antibodies targeting different regions (N-terminal, central region, or C-terminal) may provide distinct insights into protein interactions and functions .

What is the subcellular localization of PLEKHF2 and how does it change during cellular processes?

PLEKHF2 demonstrates dynamic subcellular localization:

• Under normal conditions: Diffusely distributed in the cytosol

• During endocytic processes: Localizes to early endosome membranes, colocalizing with EEA1 and RAB5 at endosomal membrane fusion hot spots

• During apoptosis: May translocate to the endoplasmic reticulum in the early phase

• During autophagy induction: Co-localizes with Akt on lysosomes

This dynamic localization is critical when designing immunofluorescence experiments, as fixation methods and timing can significantly impact detection patterns.

What criteria should be considered when selecting a PLEKHF2 antibody for specific applications?

When selecting a PLEKHF2 antibody, consider:

• Target epitope location:

  • N-terminal antibodies (AA 1-70): Useful for detecting full-length protein

  • Central region antibodies (AA 71-98): Common in commercial offerings

  • C-terminal antibodies: May detect specific isoforms

• Validated applications:

  • Western blotting: Most antibodies are validated for this application

  • Immunohistochemistry: Some antibodies work in both paraffin-embedded and frozen sections

  • ELISA: Select antibodies specifically validated for this application

• Species reactivity:

  • Human-specific: When studying human cell lines or tissues

  • Cross-reactive antibodies: For comparative studies across species (many antibodies show reactivity to human, mouse, rat, chicken, and monkey)

• Clonality:

  • Polyclonal: Broader epitope recognition but potential batch variation

  • Monoclonal: Consistent specificity but more limited epitope recognition

The application should guide your selection—for example, IP applications may require antibodies targeting accessible epitopes in the native protein conformation .

How should PLEKHF2 antibodies be validated before use in critical experiments?

A systematic validation approach for PLEKHF2 antibodies includes:

• Positive controls:

  • Verified cell lines: Jurkat and Raji cells have been confirmed as positive controls

  • Tissue controls: Human tonsil for IHC applications

  • Mouse kidney tissue for cross-reactive antibodies

• Specificity validation:

  • Western blot: Confirm single band at expected molecular weight (~28 kDa)

  • Knockout/knockdown: Compare signal in PLEKHF2-depleted vs. control samples

  • Peptide competition: Pre-incubate antibody with immunizing peptide to confirm specific binding

• Application-specific validation:

  • For IHC: Test optimal dilution range (typically 1:100-1:1000) and antigen retrieval methods

  • For WB: Optimize dilution (ranges from 1:500-1:5000 depending on antibody)

  • For IF: Verify colocalization with known interacting partners (e.g., RAB5, EEA1)

Note that the observed molecular weight may not always match the calculated 28 kDa, as post-translational modifications can affect migration patterns .

How can PLEKHF2 antibodies be optimized for immunohistochemistry applications?

For optimal IHC results with PLEKHF2 antibodies:

• Sample preparation:

  • Fixation: 10% neutral buffered formalin is recommended

  • Embedding: Paraffin embedding is suitable for most applications

  • Sectioning: 4-6 μm sections provide optimal resolution

• Antigen retrieval methods:

  • Heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) is most common

  • For some antibodies, EDTA buffer (pH 9.0) may provide better results

• Protocol optimization:

  • Dilution range: Test between 1:100-1:2500 based on antibody specifications

  • Incubation: Overnight at 4°C often yields best signal-to-noise ratio

  • Detection system: HRP-polymer based systems provide better sensitivity than ABC methods

• Controls:

  • Include human tonsil as positive control tissue

  • Use isotype controls to assess non-specific binding

  • Consider parallel staining with antibodies targeting different epitopes

The subcellular localization pattern should be assessed carefully, as PLEKHF2 can show both cytoplasmic and membrane-associated staining depending on the cellular context .

What are the critical parameters for successful Western blot detection of PLEKHF2?

For optimal Western blot detection of PLEKHF2:

• Sample preparation:

  • Lysis buffer: RIPA buffer supplemented with phosphatase and protease inhibitors

  • Denaturing conditions: Standard Laemmli buffer with β-mercaptoethanol

  • Loading amount: 20-40 μg of total protein for cell lysates

• Electrophoresis and transfer:

  • Gel percentage: 10-12% SDS-PAGE gels resolve the 28 kDa protein effectively

  • Transfer conditions: Semi-dry transfer at 15V for 30 minutes or wet transfer at 100V for 1 hour

• Antibody incubation:

  • Primary antibody dilution:

    • 1:1000-1:5000 for high-sensitivity antibodies

    • 0.04-0.4 μg/mL for concentration-specified antibodies

  • Incubation conditions: Overnight at 4°C in 5% BSA or milk in TBST

  • Secondary antibody: HRP-conjugated anti-rabbit at 1:5000-1:10000

• Detection:

  • Enhanced chemiluminescence (ECL) is sufficient for most applications

  • Expected band size: ~28 kDa, though variations may occur due to post-translational modifications

• Positive controls:

  • Jurkat or Raji cell lysates serve as reliable positive controls

  • Mouse kidney tissue for cross-reactive antibodies

Note that the observed molecular weight may differ from the predicted size due to post-translational modifications or the presence of splice variants .

How can PLEKHF2 antibodies be used to study protein-protein interactions?

PLEKHF2 antibodies can be utilized to study protein-protein interactions through several approaches:

• Co-immunoprecipitation (Co-IP):

  • Use 1-2 μg of PLEKHF2 antibody per 500 μg of protein lysate

  • Perform in non-denaturing conditions to preserve native protein interactions

  • Confirmed interactions include JIP4, as demonstrated by tandem affinity purification

  • Crosslinking with DSP or formaldehyde can capture transient interactions

• Proximity ligation assay (PLA):

  • Combine PLEKHF2 antibody with antibodies against suspected interaction partners

  • Particularly useful for detecting Phafin2-Akt interactions during autophagy

  • Requires antibodies raised in different species for optimal results

• Immunofluorescence co-localization:

  • Use antibodies against PLEKHF2 and interaction partners (e.g., RAB5, EEA1)

  • Particularly effective for studying endosomal localization

  • PLEKHF2 has been shown to colocalize with EEA1 and RAB5 at endosomal membrane fusion sites

• Pull-down assays:

  • LAP-tagged Phafin2 has been successfully used in tandem affinity purification

  • Mass spectrometry analysis identified JIP4 as a strong interactor with 28-fold enrichment

These methods have revealed important interactions between PLEKHF2 and proteins involved in membrane trafficking and signaling pathways.

How can PLEKHF2 antibodies be utilized to study its role in macropinocytosis and endosomal trafficking?

To investigate PLEKHF2's role in macropinocytosis and endosomal trafficking:

• Live-cell imaging with fluorescent PLEKHF2 antibody fragments:

  • Fab fragments conjugated to fluorophores can track PLEKHF2 dynamics

  • Combine with markers for early endosomes (EEA1) and macropinosomes (dextran)

  • This approach has revealed PLEKHF2's recruitment to retromer-containing tubules of macropinosomes

• Immunofluorescence co-staining protocol:

  • Fix cells at different time points after macropinocytosis induction

  • Co-stain for PLEKHF2 and JIP4 to analyze their temporal recruitment

  • Include markers for actin (phalloidin) to visualize actin reorganization at macropinosomes

  • This method demonstrated that PLEKHF2 promotes recycling tubules on macropinosomes

• Functional assays with antibody-mediated inhibition:

  • Microinjection of function-blocking PLEKHF2 antibodies

  • Monitor uptake of fluorescent dextran to assess macropinocytosis efficiency

  • Quantify the density of tubular structures on macropinosomes

• Biochemical fractionation with antibody detection:

  • Isolate early endosomal fractions using sucrose gradient centrifugation

  • Use PLEKHF2 antibodies to detect protein levels in different fractions

  • Compare with RAB5 and other endosomal markers

This multi-faceted approach has revealed that PLEKHF2 plays crucial roles in coordinating actin organization during macropinosome formation and promoting recycling tubules on macropinosomes .

What experimental approaches can be used to study PLEKHF2's role in TNF-induced apoptosis?

To investigate PLEKHF2's role in TNF-induced apoptosis:

• Apoptosis induction and monitoring:

  • Treat cells with TNF-α (10-50 ng/mL) with or without cycloheximide

  • Use PLEKHF2 antibodies to track protein localization during apoptosis progression

  • This has revealed PLEKHF2's translocation to the endoplasmic reticulum during early apoptosis

• Structure-function analysis:

  • Generate domain-specific mutants of PLEKHF2 (PH domain, FYVE domain)

  • Use antibodies to confirm expression and analyze localization of mutants

  • Assess apoptotic response to TNF-α in cells expressing these mutants

  • This approach demonstrated the importance of both domains for PLEKHF2's pro-apoptotic function

• Protein complex analysis:

  • Perform co-immunoprecipitation with PLEKHF2 antibodies at different time points after TNF-α treatment

  • Analyze associated proteins by mass spectrometry

  • Focus on changes in interactions during the apoptotic cascade

• Subcellular fractionation with antibody detection:

  • Isolate ER, mitochondrial, and cytosolic fractions at different time points after TNF-α treatment

  • Use PLEKHF2 antibodies to track protein redistribution between compartments

  • This has shown PLEKHF2's involvement in the ER-mitochondrial apoptotic pathway

These approaches have demonstrated that PLEKHF2 enhances cellular sensitivity to TNF-induced apoptosis, potentially through its redistribution to the endoplasmic reticulum and subsequent involvement in the ER-mitochondrial apoptotic pathway .

What are common issues when using PLEKHF2 antibodies and how can they be resolved?

When working with PLEKHF2 antibodies, researchers may encounter several challenges:

• Inconsistent band size in Western blotting:

  • Issue: Observed molecular weight differs from the calculated 28 kDa

  • Solution: This is expected as protein mobility can be affected by post-translational modifications

  • Validation approach: Use positive control lysates from Jurkat or Raji cells

• High background in immunohistochemistry:

  • Issue: Non-specific staining obscures specific PLEKHF2 signal

  • Solution:

    • Optimize antibody concentration (try 1:100-1:2500 dilution range)

    • Use more stringent washing (0.1% Tween-20 in PBS)

    • Block with 5% BSA instead of serum

  • Validation: Include isotype control and compare staining pattern with literature

• Weak signal in immunofluorescence:

  • Issue: Low detection of PLEKHF2 despite confirmed expression

  • Solution:

    • Test different fixation methods (4% PFA vs. methanol)

    • Try antigen retrieval even for IF applications

    • Use tyramide signal amplification for weak signals

  • Optimization: PLEKHF2 may relocalize during fixation; compare live-cell imaging results

• Cross-reactivity with other proteins:

  • Issue: Antibody detects non-specific proteins

  • Solution:

    • Use antibodies targeting different epitopes for confirmation

    • Validate with PLEKHF2 knockdown/knockout samples

    • Consider using more specific monoclonal antibodies when available

• Storage-related issues:

  • Issue: Reduced antibody activity after storage

  • Solution:

    • Store at -20°C in small aliquots to avoid freeze-thaw cycles

    • Add 50% glycerol to prevent freezing damage in some formulations

    • For short-term storage (1-2 weeks), 4°C is acceptable

Following these troubleshooting approaches will help ensure reliable results when working with PLEKHF2 antibodies.

How can researchers optimize methods for detecting PLEKHF2 in challenging samples or low-expression conditions?

For detecting PLEKHF2 in challenging conditions:

• Low expression scenarios:

  • Enrichment strategies:

    • Perform subcellular fractionation to concentrate endosomal fractions

    • Immunoprecipitate PLEKHF2 before Western blotting

  • Signal amplification methods:

    • Use high-sensitivity ECL substrates for Western blotting

    • Apply tyramide signal amplification for immunohistochemistry

    • Consider quantum dot-conjugated secondary antibodies for long-lasting signals

• Difficult tissue samples:

  • Optimization of fixation:

    • Test progressive fixation times (4, 8, 12, 24 hours)

    • Compare cross-linking (formaldehyde) vs. precipitating (methanol) fixatives

  • Antigen retrieval methods:

    • Compare heat-induced (citrate, EDTA, Tris buffers) vs. enzymatic retrieval

    • Optimize pH (6.0 vs. 9.0) for maximum epitope exposure

  • Alternative detection strategies:

    • Consider chromogenic vs. fluorescent detection systems

    • Use polymer-based detection for improved sensitivity

• Precious samples with limited material:

  • Miniaturized protocols:

    • Capillary Western technology (ProteinSimple)

    • Reverse phase protein arrays

  • Multiplexing strategies:

    • Sequential stripping and reprobing

    • Multiplex immunofluorescence with spectrally distinct fluorophores

• Complex samples with high background:

  • Pre-absorption strategies:

    • Pre-absorb antibodies with tissues lacking PLEKHF2 expression

    • Use species-matched control IgG at the same concentration

  • Alternative blocking agents:

    • Test commercial protein-free blockers

    • Consider 5% milk vs. 5% BSA vs. fish gelatin for optimal results

These optimized approaches have been validated in studies detecting PLEKHF2 in diverse experimental contexts from cell lines to complex tissue samples.

What are the latest methodological advances in antibody-based detection of PLEKHF2 and related proteins?

Recent methodological advances for PLEKHF2 antibody applications include:

• Proximity-based detection technologies:

  • Proximity ligation assay (PLA):

    • Detects PLEKHF2 interactions with partners like Akt and JIP4

    • Provides single-molecule resolution of protein complexes

    • Has revealed novel interactions in the endosomal pathway

  • FRET-based antibody pairs:

    • Allows real-time monitoring of PLEKHF2 conformational changes

    • Useful for studying domain interactions during signaling events

• Super-resolution microscopy techniques:

  • STORM/PALM microscopy:

    • Achieves ~20nm resolution of PLEKHF2 localization

    • Reveals previously undetectable subendosomal distributions

  • Expansion microscopy:

    • Physical expansion of samples improves resolution with standard antibodies

    • Particularly useful for studying PLEKHF2's role at endosomal contact sites

• Antibody engineering approaches:

  • Nanobodies and single-domain antibodies:

    • Smaller size allows better penetration and epitope access

    • Reduced background in complex samples

  • Bispecific antibody fragments:

    • Target PLEKHF2 and binding partners simultaneously

    • Useful for studying transient interactions in living cells

• Integration with other technologies:

  • Mass cytometry (CyTOF) with metal-tagged antibodies:

    • Allows multiplexed detection of PLEKHF2 and dozens of other proteins

    • Useful for systems-level analysis of signaling networks

  • CITE-seq approaches:

    • Combines antibody detection with transcriptomics

    • Links PLEKHF2 protein levels to broader gene expression patterns

• Advanced computational analysis:

  • Machine learning algorithms:

    • Improve signal extraction from noisy immunofluorescence data

    • Identify subtle patterns in PLEKHF2 distribution not visible to human observers

  • Cloud-based image analysis platforms:

    • Enable collaborative analysis of large antibody-based datasets

    • Apply standardized quantification across multiple experiments

These methodological advances are beginning to reveal new insights into the dynamic behavior and interactions of PLEKHF2 in various cellular contexts .